High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: A novel mechanism for contact activation

Blood

Volumn 91, Issue 2, 1998, Pages 516-528

  Motta, Guacyara ^b   Rojkjaer, Rasmus ^b   Hasan, Ahmed A K ^b   Cines, Douglas B ^b   Schmaier, Alvin H ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 12; KALLIKREIN; KININOGEN; PLASMIN; PLASMINOGEN; PREKALLIKREIN; PROUROKINASE; THIOL PROTEINASE;

ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HUMAN CELL; KALLIKREIN KININ SYSTEM; PRIORITY JOURNAL; PROTEIN ASSEMBLY;

EID: 0031973492     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.2.516.516_516_528     Document Type: Article

References (54)

1. Goodnough LT, Saito H, Ratnoff OD: Thrombosis or myocardial infarction in congenital clotting factor abnormalities and chronic thrombocytopenias: a report of 21 patients and a review of 50 previously reported cases. Medicine 62:248, 1983
2. Halbmayer WM, Haushofer A, Schon A, Mannhalter C, Stromer E, Baumgarter K, Fischer M: The prevalence of moderate and severe factor XII (Hageman factor) deficiency among the normal population: Evaluation of the incidence of factor XII deficiency among 300 healthy blood donors. Thromb Haemost 71:68, 1994
3. Lammle B, Wuillemin WA, Huber I, Krauskopf M, Zurcher C, Pflugshaupt R, Furlan M: Thromboembolism and bleeding tendency in congenital factor XII deficiency-A study on 74 subjects from 14 Swiss families. Thromb Haemost 65:117, 1991
4. Halbmayer WM, Mannhalter C, Feichtinger C, Rubi K, Fisher M: The prevalence of factor XII deficiency in 103 orally anticoagulated outpatients suffering from recurrent venous and/or arterial thromboembolism. Thromb Haemost 68:285, 1992
5. Von Kanel R, Wuillemin WA, Furlan M, Lammle B: Factor XII clotting activity and antigen levels in patients with thromboembolic disease. Blood Coag Fibrinol 3:555, 1992
6. Jespersen J, Munkvad S, Pedersen OD, Gram J: Evidence for a role of factor XII-dependent fibrinolysis in cardiovascular diseases. Ann NY Acad Sci 667:454, 1992
7. Munkvad S, Jespersen J, Gram J, Kluft C: Long-lasting depression of the factor XII-dependent fibrinolytic system in patients with myocardial infarction undergoing thrombolytic therapy with recombinant tissue-type plasminogen activator: A randomized placebo-controlled study. J Am College Cardiol 17:957, 1991
8. Niewiarowski S, Prou-Wartelle O: The role of Hageman factor in fibrinolysis. Thromb Diath Haemorrh 3:593, 1959
9. Levi M, Hack CE, de Boer JP, Brandjes DPM, Buller HR, ten Cate JW: Reduction of contact activation related fibrinolytic activity in factor XII deficient patients. Further evidence for the role of the contact system in fibrinolysis in vivo. J Clin Invest 88:1155, 1991
10. Colman RW: Activation of plasminogen by human plasma kallikrein. Biochem Biophys Res Commun 35:273, 1969
11. Mandle RJ Jr, Kaplan AP: Hageman factor substrates. Human plasma prekallikrein: Mechanism of activation by Hageman factor and participation in Hageman-factor-dependent fibrinolysis. J Biol Chem 252:6097, 1977
12. Goldsmith G, Saito H, Ratnoff OD: The activation of plasminogen by Hageman factor (factor XII) and Hageman factor fragments. J Clin Invest 62:54, 1978
13. Mandle RJ Jr, Kaplan AP: Hageman-factor-dependent fibrinolysis: Generation of fibrinolytic activity by the interaction of human activated factor XI and plasminogen. Blood 54:850, 1979
14. Miles LA, Greengard JS, Griffin JH: A comparison of the abilities of plasma kallikrein, beta-factor XIIa, factor XIa and urokinase to activate plasminogen. Thromb Res 29:407, 1983
15. Ichinose A, Fujikawa K, Suyama T: The activation of prourokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 261:3486, 1986
16. Gurewich V, Johnstone M, Loza J-P, Pannell R: Pro-urokinase and prekallikrein are both associated with platelets. Implications for the intrinsic pathway of fibrinolysis and for therapeutic thrombolysis. FEES Lett 318:317, 1993
17. Loza J-P, Gurewich V, Johnstone M, Pannell R: Platelet-bound prekallikrein promotes pro-urokinase-induced clot lysis: a mechanism for targeting the factor XII dependent intrinsic pathway of fibrinolysis. Thromb Haemost 71:347, 1994
18. Lenich C, Pannell R, Gurewich V: Assembly and activation of the intrinsic fibrinolytic pathway on the surface of human endothelial cells in culture. Thromb Haemost 74:698, 1995
19. Greengard JS, Griffin JH: Receptors for high molecular weight kininogen on stimulated washed human platelets. Biochemistry 23: 6863, 1984
20. Gustafson EJ, Schutsky D, Knight LC, Schmaier AH: High molecular weight kininogen binds to unstimulated platelets. J Clin Invest 78:310, 1986
21. Schmaier AH, Kuo A, Lundberg D, Murray S, Cines DB: Expression of high molecular weight kininogen on human umbilical vein endothelial cells. J Biol Chem 263:16327, 1988
22. Van Iwaarden F, de Groot PG, Bouma BN: The binding of high molecular weight kininogen to cultured human endothelial cells. J Biol Chem 263:4698, 1988
23. Meloni FJ, Schmaier AH: Low molecular weight kininogen binds to platelets to modulate thrombin-induced platelet activation. J Biol Chem 266:6786, 1991
24. Jiang Y, Muller-Esterl W, Schmaier AH: Domain 3 of kininogens contains a cell binding site and a site that modifies thrombin activation of platelets. J Biol Chem 267:3712, 1992
25. Hasan AAK, Cines DB, Ngaiza JR, Jaffe EA, Schmaier AH: High molecular weight kininogen is exclusively membrane bound on endothelial cells to influence activation of vascular endothelial cells. Blood 85:3134, 1995
26. Hasan AAK, Cines DB, Zhang J, Schmaier AH: The C-terminus of bradykinin and N-terminus of the light chain of kininogens comprise an endothelial cell binding domain. J Biol Chem 269;31822, 1994
27. Herwald H, Hasan AAK, Godovac-Zimmermann J, Schmaier AH, Müller-Esterl W: Identification of an endothelial cell binding site on kininogens' domain D3. J Biol Chem 270:14634, 1995
28. Hasan AAK, Cines DB, Herwald H, Schmaier AH, Müller-Esterl W: Mapping the cell binding site on high molecular weight kininogen's domain 5. J Biol Chem 270:19256, 1995
29. Mandle R Jr, Colman RW, Kaplan AP: Identification of prekallikrein and high molecular weight kininogen as a complex in human plasma. Proc Natl Acad Sci USA 73:4179, 1976
30. Scott CF, Colman RW: Function and immunochemistry of prekallikrein-high molecular weight kininogen complex in plasma. J Clin Invest 65:413, 1980
31. Tait JF, Fujikawa K: Identification of the binding site for plasma prekallikrein in human high molecular weight kininogen. A region from residues 185 to 224 of the kininogen light chain retains full binding activity. J Biol Chem 261:15396, 1986
32. Reddigari SR, Shibayama Y, Brunnee T, Kaplan AP: Human Hageman factor (factor XII) and high molecular weight kininogen compete for the same binding site on human umbilical vein endothelial cells. J Biol Chem 268:11982, 1993
33. Fisher CA, Schmaier AH, Addonizio VP, Colman RW: Assay of prekallikrein: Comparison of amidolytic, esterolytic, coagulation and immunochemical assays. Blood 59:963, 1982
34. Schmaier AH, Smith PM, Colman RW: Platelet C1 inhibitor: A secreted alpha granule protein. J Clin Invest 75:242, 1985
35. Kaufmann J, Haasemann M, Modrow S, Muller-Esterl W: Structural dissection of the multidomain kininogens. Fine mapping of the target epitopes of antibodies interfering with their functional properties. J Biol Chem 268:9079, 1993
36. Hock J, Vogel R, Linke RP, Muller-Esterl W: High molecular weight kininogen-binding site of prekallikrein probed by monoclonal antibodies. J Biol Chem 265:12005, 1990
37. Motta G, Fink E, Sampaio MV, Sampaio CAM: Human plasma kallikrein processing: proteolysis as an alternative control. Agents Actions Suppl 38:265, 1992
38. Schmaier AH, Colman RW: Platelet high molecular weight kininogen: Identification and mechanisms of availability. Methods Enzymol 169:276, 1989
39. Hasan AAK, Zhang J, Samuels M, Schmaier AH: Conformational changes in low molecular weight kininogen alters its ability to bind to endothelial cells. Thromb Haemost 74:1088, 1995
40. Bock PE, Shore JD: Protein-protein interactions in contact activation of blood coagulation. Characterization of ftuorescein-labeled human high molecular weight kininogen-light chain as a probe. J Biol Chem 258:15079, 1983
41. Green NM: A spectrophotometric assay for avidin and biotin on binding of dyes by avidin. Biochem J 94:23, 1965
42. Scatchard G: The attraction of proteins for small molecules and ions. Ann NY Acad Sci 51:660, 1949
43. Müller R: Determination of affinity and specificity of anti-hapten antibodies by competitive radioimmunoassay. Methods Enzymol 92: 589, 1983
44. Schmaier AH, Farber A, Schein R, Sprung C: Structural changes of plasma high molecular weight kininogen afterin vitro activation and, in sepsis. J Lab Clin Med 112:182, 1988
45. Barnathan ES, Kuo A, Rosenfeld L, Kariko K, Leski M, Robbiati F, Cines DB: Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells. J Biol Chem 265:2865, 1990
46. Bock PE, Shore JD, Tans G, Griffin JH: Protein-protein interactions in contact activation of blood coagulation. Binding of high molecular weight kininogen and the 5-(iodoacetamido) fluorescein-labeled kininogen light chain to prekallikrein, kallikrein, and the separated kallikrein heavy and light chains. J Biol Chem 260:12434, 1985
47. Bradford HN, Schmaier AH, Colman RW: Kinetics of inhibition of platelet calpain II by human kininogens. Biochem J 270:83, 1990
48. Wiggins RC, Loskutoff DJ, Cochrane CG, Girffin JH: Activation of rabbit Hageman factor by homogenates of cultured rabbit endothelial cells. J Clin Invest 65:197, 1980
49. Meloni FJ, Gustafson EJ, Schmaier AH: High molecular weight kininogen binds to platelets by its heavy and light chains and when bound has altered susceptibility to kallikrein cleavage. Blood 79:1233, 1992
50. Rocha E, Suva M, Beraldo WT, Rosenfeld G: Bradykinin, hypotensive and smooth muscle stimulator released from plasma globulin by snake venoms and by trypsin. Am J Physiol 156:261, 1949
51. Smith D, Gilbert M, Owen WG: Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 66:835, 1983
52. Brown NJ, Nadeau JH, Vaughan DE: Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost 77:522, 1997
53. Carmeliet P, Collen D: Gene targeting and gene transfer studies of the plasminogen/plasmin system: Implications in thrombosis, hemostasis, neointima formation, and atherosclerosis. FASEB J 9:934, 1995
54. Higazi A, Cohen RL, Henkin J, Kniss D, Schwartz BS, Cines DB Enhancement of the enzymatic activity of single-chain urokinase plasminogen activator by soluble urokinase receptor. J Biol Chem 270:17375, 1995